RCUS insider trading
NYSE HealthcareArcus Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Company website: arcusbio.com
RCUS insider activity at a glance
FilingIQ has scored 350 insider transactions for RCUS since Mar 19, 2018. The most recent filing in our index is dated May 11, 2026.
Across the full history, 49 open-market purchases
and 142 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RCUS insider trades is 57.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RCUS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding RCUS
Frequently asked
- How many insider trades does FilingIQ track for RCUS?
- FilingIQ tracks 350 Form 4 insider transactions for RCUS (Arcus Biosciences, Inc.), covering filings from Mar 19, 2018 onwards. 1 of those were filed in the last 90 days.
- Are RCUS insiders net buyers or net sellers?
- Across the full Form 4 history for RCUS, 49 transactions (14%) were open-market purchases and 142 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RCUS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is RCUS in?
- Arcus Biosciences, Inc. (RCUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.69B.
Methodology & sources
Every RCUS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.